J.P. Morgan Securities discloses Kangji Medical share dealings in privatization scheme

J.P. Morgan Securities PLC, acting as a Class (5) associate connected with the Offeror, has disclosed dealings in Kangji Medical Holdings Limited shares under Rule 22 of the Hong Kong Code on Takeovers and Mergers. The transactions, made for its own account, occurred on November 11, 2025.

The disclosures detail three closing out transactions of derivative contracts. Two of these involved 500 reference securities each, with maturity dates of September 24, 2027, and executed at a price of $9.1874 per security, totaling $4,593.7000 each. The third closing out transaction involved 3,500 reference securities, with a maturity date of December 29, 2025, at $9.1799 per security, totaling $32,129.6500. Additionally, J.P. Morgan Securities PLC issued a derivative involving 1,000 reference securities with a maturity date of December 15, 2026, at $9.2031 per security, totaling $9,203.1000.

Following these dealings, the resultant balance of shares held, including those subject to agreement or understanding, was 8,772,843 after the initial closing out, decreasing to 8,771,843 after the subsequent transactions, and ultimately returning to 8,772,843 after the derivative issue. J.P. Morgan Securities PLC is ultimately owned by JPMorgan Chase & Co.